Title |
Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies
|
---|---|
Published in |
BMC Systems Biology, November 2011
|
DOI | 10.1186/1752-0509-5-193 |
Pubmed ID | |
Authors |
Stacey D Finley, Marianne O Engel-Stefanini, PI Imoukhuede, Aleksander S Popel |
Abstract |
Vascular endothelial growth factor (VEGF) is a potent regulator of angiogenesis, and its role in cancer biology has been widely studied. Many cancer therapies target angiogenesis, with a focus being on VEGF-mediated signaling such as antibodies to VEGF. However, it is difficult to predict the effects of VEGF-neutralizing agents. We have developed a whole-body model of VEGF kinetics and transport under pathological conditions (in the presence of breast tumor). The model includes two major VEGF isoforms VEGF121 and VEGF165, receptors VEGFR1, VEGFR2 and co-receptors Neuropilin-1 and Neuropilin-2. We have added receptors on parenchymal cells (muscle fibers and tumor cells), and incorporated experimental data for the cell surface density of receptors on the endothelial cells, myocytes, and tumor cells. The model is applied to investigate the action of VEGF-neutralizing agents (called "anti-VEGF") in the treatment of cancer. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 1% |
Unknown | 66 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 13 | 19% |
Researcher | 10 | 15% |
Student > Master | 10 | 15% |
Student > Bachelor | 9 | 13% |
Student > Doctoral Student | 5 | 7% |
Other | 8 | 12% |
Unknown | 12 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Engineering | 20 | 30% |
Agricultural and Biological Sciences | 12 | 18% |
Medicine and Dentistry | 10 | 15% |
Biochemistry, Genetics and Molecular Biology | 8 | 12% |
Chemistry | 2 | 3% |
Other | 4 | 6% |
Unknown | 11 | 16% |